SCHEMBL7678017

SCHEMBL7678017

O=C(N/N=C\c1ccc([N+](=O)[O-])cc1)c1[nH]c2ccccc2c1-c1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.57
MEN1 O00255 7/20 0.57
KMT2A Q03164 7/20 0.57
LMNA P02545 7/20 0.57
SMN1; SMN2 Q16637 6/20 0.57
POLB P06746 3/20 0.57
RAB9A P51151 3/20 0.57
GAA P10253 2/20 0.57
TUBB4A P04350 2/20 0.57
TUBB P07437 2/20 0.57
TUBA3C P0DPH7 2/20 0.57
TUBA1B P68363 2/20 0.57
TUBA4A P68366 2/20 0.57
TUBB4B P68371 2/20 0.57
TUBB3 Q13509 2/20 0.57
TUBB2A Q13885 2/20 0.57
TUBB8 Q3ZCM7 2/20 0.57
TUBA3E Q6PEY2 2/20 0.57
TUBA1A Q71U36 2/20 0.57
TUBA1C Q9BQE3 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7678021 1.00 MAPT (0.57) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL7559850 0.91 TUBB4A (0.66) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL7559855 0.91 TUBB4A (0.66) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL7679897 0.90 MAPT (0.57) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL7679901 0.90 MAPT (0.57) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL12136736 0.89 TUBB4A (0.73) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL7673252 0.88 TUBB4A (0.70) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL7530637 0.88 TUBB4A (0.70) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL7560613 0.86 MAPT (0.66) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL7562479 0.86 TUBB4A (0.63) MAPTMEN1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885MEN1 3165/4885KMT2A 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.